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Overweight and obesity, caused mainly by unhealthy 
lifestyles and genetic predisposition, have become 
pandemic.1 These disorders of excess body fat have 
been known for many years to be linked to increased 
cardiovascular morbidity and mortality. Additionally, 
excess bodyweight is associated with increased overall 
mortality due to disorders such as cancer,2 sleep apnoea,3 
and Alzheimer’s disease.4
With regard to cardiovascular outcomes, classic 
risk factors such as arterial hypertension, lipid 
abnormalities, and dysglycaemia are important 
constituents of disease and mortality hazards. Findings 
from one study5 showed that the eﬀ ects of obesity 
on blood pressure and cholesterol could account for 
about 45% of the increased risk of coronary heart 
disease. For moderate overweight, an increased risk 
of coronary heart disease remains, independent of 
these traditional risk factors, although this ﬁ nding is 
debated.
In The Lancet, the Global Burden of Metabolic Risk 
Factors for Chronic Diseases Collaboration (BMI 
Mediated Eﬀ ects)6 reports a large collaborative 
study on the role of overweight and obesity on risk 
of coronary heart disease and stroke, and on the 
contributions of blood pressure, dyslipidaemia, and 
glucose concentration both singly and in combination. 
The study, which included nearly 2 million individuals 
of diﬀ erent ethnicity from around the world, increases 
our understanding of coronary heart disease and 
stroke. The three major risk factors—often associated 
with overweight and obesity—explain roughly 
50% of the cardiovascular outcomes recorded. This 
ﬁ nding is a conﬁ rmation of previous analyses, but 
the report provides a strong and detailed dissection 
of the individual contribution of each risk factor. The 
impressive number of individuals included, derived 
from more than 90 diﬀ erent published studies, 
allowed for a reliable analysis of the weight of diﬀ erent 
risk factors, not only in the total population but in 
various subgroups of patients, types of events, and 
regions. For coronary events, blood pressure is the 
most important risk factor, followed by glucose and 
cholesterol. For stroke, risk factor analysis suggested 
that up to 76% of the excess risk (95% CI 65–91) was 
mediated by the combined three risk factors, with 
an even stronger role for hypertension. Sensitivity 
analyses of waist circumference and waist-to-hip ratio 
in addition to BMI conﬁ rmed the strength of these 
conclusions.
The study also presents an analysis of the 
overweight subgroup, and conﬁ rms the previously 
debated ﬁ nding of the deleterious and troublesome 
eﬀ ect of overweight on the investigated endpoints. 
This ﬁ nding emphasises the importance of weight 
management and early intervention of modiﬁ able risk 
factors in overweight patients. To avoid a negative 
cardiovascular outcome, management of risk factors, 
either separately or, preferably, in combination, 
remains a major target for physicians, with an extra 
emphasis on weight loss. In a recent National Health 
and Nutrition Examination Survey (NHANES) analysis,7 
63·7% of overweight and 42·6% of obese individuals 
were classiﬁ ed as hypertensive, with similar ﬁ gures for 
hypercholesterolaemia. Unfortunately, by focusing on 
risk-factor targets, many patients do not reach targets 
for blood pressure and cholesterol.8 Findings from 
studies show that 50% of patients’ blood pressure 
remains uncontrolled.8 Thus, although these patients 
are unmistakably at signiﬁ cant risk, overweight and 
obese individuals are the group most likely to be poorly 
treated for blood pressure and cholesterol because of 
medical inertia and physicians believing, or hoping, that 
weight loss alone will suﬃ  ce. These epidemiological 
data not only conﬁ rm and extend our knowledge 
on the association between excess bodyweight and 
cardiovascular disease, but, more importantly, summon 
clinicians to translate these ﬁ ndings into imminent 
obesity management action.
The present results could also help to explain why 
decreased use of agents that lower blood pressure and 
statins in the intensive lifestyle arm of Look Ahead—a 
study stopped in September, 2012, because of futility—
might have contributed to the disappointing outcome 
results of that intervention trial, despite the intensive 
eﬀ orts and the weight loss and cardiorespiratory 
ﬁ tness achieved.9 However, signiﬁ cant outcome 
improvement can be achieved when a multifactorial 
approach is applied. For example, in the Steno-2 
trial,10 in patients with diabetes, appropriate reduction 
of blood pressure, glucose control, prescription of 
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At the 2013 European Respiratory Society (ERS) Annual 
Congress, the European Lung White Book was launched 
which showed that in the WHO-deﬁ ned European 
region one in ten deaths are caused by either chronic 
obstructive pulmonary disease (COPD), lung cancer, 
tuberculosis, or a lower respiratory tract infection such 
as pneumonia. The landscape was much the same in the 
ﬁ rst version of the white book published 10 years ago, 
and, even more alarmingly, WHO reports that one in six 
deaths worldwide result from these four lung diseases. 
Many of you are involved in exciting research projects 
to tackle these diseases and advance respiratory health, 
Respiratory medicine and critical care: a call for papers
statins, and lifestyle intervention led to a rapid, 
signiﬁ cant, and clinically relevant improvement of 
cardiovascular outcome. We might learn from these 
diabetes outcome data for overweight patients with 
comorbidities. 
With regard to what, when, and how treatment should 
be given, no clear suggestions can be derived from the 
study by the Global Burden of Metabolic Risk Factors for 
Chronic Diseases Collaboration (BMI Mediated Eﬀ ects).6 
Despite substantial evidence of the merits of salt 
restriction and a trend in Europe towards low sodium 
intake, whether more stringent measures should be 
taken for blood pressure and circulating lipid reduction 
in obese individuals can be questioned. Should earlier 
interventions and more aggressive targets be the focus, 
as they have been (with success) for patients with 
diabetes? Additionally, more attention should be given 
to preventive measures—ie, avoidance of sugar and 
fructose sweetened beverages.
In the accompanying study,6 50% of the overall 
cardio vascular disease risk remains unexplained and 
underexplored. In view of the role of the sympathetic 
nervous system in obesity, and the potential risk 
of raised heart rate,11 the addition of heart rate in 
the model would have been interesting. Therefore, 
future research should examine other mechanisms 
linking obesity to cardiovascular disease, including 
inﬂ ammation, cytokine excess and oxidative stress, 
and cardiorespiratory ﬁ tness.12 Finally, future 
consideration of drug treatment for overweight and 
obesity, potentially tackling the remaining 50% of risk, 
should include the assessment of drugs in terms of 
their eﬀ ects on blood pressure, lipids, and ultimately 
on cardiovascular outcomes.
The clinical message undoubtedly remains the same—
early and appropriate interventions are needed, even in 
moderately obese individuals. In all patients with excess 
bodyweight, physicians should rigorously target blood 
pressure, lipid parameters, and glucose abnormalities, 
and simultaneously emphasise weight loss and 
improvement of cardiorespiratory ﬁ tness.
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